Innovent Biologics Publishes Phase 1 Study Results on IBI343 for Advanced Gastric Cancer Innovent Biologics has released Phase 1 clinical trial findings for IBI343, targeting advanced gastric cancer. The study results published in Nature Medicine showcase promising efficacy.

Innovent Biologics Publishes Phase 1 Study Results on IBI343 for Advanced Gastric Cancer #China #Suzhou #Innovent_Biologics #gastric_cancer #IBI343

Innovent Biologics Shares Promising Phase 1 Results for IBI343 in Pancreatic Cancer Treatment at ASCO 2025 At ASCO 2025, Innovent Biologics presented updated Phase 1 trial data on IBI343, showing promising efficacy in patients with advanced pancreatic cancer.

Innovent Biologics Shares Promising Phase 1 Results for IBI343 in Pancreatic Cancer Treatment at ASCO 2025 #China #Suzhou #Innovent_Biologics #IBI343 #ASCO_2025

Innovent Set to Showcase Breakthrough Clinical Findings at ASCO 2025 Annual Meeting Innovent Biologics will unveil significant clinical data at the 2025 ASCO Annual Meeting, highlighting IBI363 and IBI343 breakthrough drug candidates.

Innovent Set to Showcase Breakthrough Clinical Findings at ASCO 2025 Annual Meeting #USA #Chicago #IBI343 #Innovent #IBI363

Innovent's IBI343 Achieves Breakthrough Therapy Status for Advanced Pancreatic Cancer Treatment Innovent Biologics has achieved Breakthrough Therapy Designation for IBI343, targeting advanced pancreatic cancer, promising improved outcomes for patients.

Innovent's IBI343 Achieves Breakthrough Therapy Status for Advanced Pancreatic Cancer Treatment #China #Suzhou #Innovent_Biologics #pancreatic_cancer #IBI343

Innovent's Promising Phase 1 Data on IBI343 for Advanced Pancreatic Cancer Shines at ESMO Asia Congress 2024 Innovent Biologics reveals updated data from its Phase 1 trial for IBI343 in treating advanced pancreatic cancer at ESMO Asia 2024, highlighting efficacy and safety.

Innovent's Promising Phase 1 Data on IBI343 for Advanced Pancreatic Cancer Shines at ESMO Asia Congress 2024 #Innovent_Biologics #pancreatic_cancer #IBI343